Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing
Executive Summary
Bristol-Myers Squibb's decision not to seek accelerated FDA approval for its Opdivo/Yervoy combo in early lung cancer shocked investors - but analysts still expect a filing to come, albeit later than first thought.